Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
-	Pertuzumab	Perjeta®	Is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.	Assessment Process Complete	31st January 2019
-	Pertuzumab	Perjeta®	The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.	Assessment Process Complete	28th August 2013
-	Pertuzumab	Perjeta®	Is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.	Assessment Process Complete	11th May 2016
20053	Pertuzumab and trastuzumab	Phesgo®	For the treatment of Early breast cancer and Metastatic breast cancer	Rapid Review Complete	6th January 2021
-	Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride	Fydrane®	Is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.	Rapid Review Complete	20th December 2016
-	Piperaquine tetraphosphate/dihidroartemisinin	Eurartesim®	For uncomplicated malaria caused by the Plasmodium falciparum parasite	Rapid Review Complete	28th May 2012
-	Pirfenidone	Esbriet®	For the treatment of mild to moderate idiopathic pulmonary fibrosis.	Assessment Process Complete	20th March 2013
-	Pitavastatin	Livazo®	Is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.	Rapid Review Complete	29th December 2010
-	Pitolisant hydrochloride	Wakix®	For the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.	Rapid Review Complete	15th June 2017
23054	Pitolisant hydrochloride	Wakix®	Pitolisant hydrochloride (Wakix®) is indicated in adults, adolescents, and children aged 6 years and older for the treatment of narcolepsy with or without cataplexy	Rapid Review Complete	4th October 2023
-	Pixantrone	Pixuvri®	Is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL).	Rapid Review Complete	20th March 2015
19052	Polatuzumab vedotin	Polivy®	In combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).	Assessment Process Complete	16th February 2021
22043	Polatuzumab vedotin	Polivy®	In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).	NCPE Assessment Process Complete	5th December 2023
-	Polynuclear iron(III)-oxyhydroxide (pn-FeOOH)	Velphoro®	Is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Rapid Review	Rapid Review Complete	8th October 2014
-	Pomalidomide	Imnovid®)	In combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.	Assessment Process Complete	13th March 2015
22016	Pomalidomide	Imnovid®	In combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.	Rapid Review Complete	5th May 2022
-	Ponatinib	Iclusig®	Is indicated for patients in chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation and for Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	Assessment Process Complete	4th January 2016
21036	Ponesimod	Ponvory®	For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Rapid Review Complete	8th October 2021
-	Prasugrel	Efient®	For the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.	Assessment Process Complete	1st February 2010
-	Pregabalin	Lyrica®	For the treatment of Generalised Anxiety Disorder.	Full HTA Assessment	15th December 2014
-	Pregabalin	Lyrica®	For the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.	Full HTA Assessment	12th June 2015
-	Progesterone (micronised)	Utrogestan®	Progesterone (micronised) is indicated in women for supplementation of the luteal phase during ART cycles.	Rapid Review Complete	20th November 2019
-	Prucalopride	Resolor®	For the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.	Rapid Review Complete	29th March 2011
24006	Quizartinib	Vanflyta®	Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia that is FLT3-ITD positive.	Rapid Review Complete	11th March 2024
-	Radium-223	Xofigo®	For the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.	Assessment Process Complete	12th December 2014
-	Ramucirumab	Cyramza®	In combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.	Assessment Process Complete	26th July 2016
-	Ranolazine	Ranexa®	Cost-effectiveness of Ranolazine (Ranexa®)	Rapid Review Complete	19th November 2009
19054	Ravulizumab	Ultomiris®	For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.	Assessment Process Complete	30th May 2022
20036	Ravulizumab	Ultomiris®	Indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve, or have received eculizumab for at least 3 months and have evidence of response to eculizumab.	Assessment Process Complete	28th July 2022
-	Recombinant Human Parathyroid Hormone	Natpar®	Is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.	Rapid Review Complete	21st May 2018
-	Regadenoson	Rapiscan®	Cost-effectiveness of Regadenoson (Rapiscan®)	Rapid Review Complete	2nd November 2011
21065	Regdanvimab	RegkironaTM	For the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.	Rapid Review Complete	10th January 2022
-	Regorafenib	Stivarga®	For the treatment of patients with gastrointestinal stromal tumours (GIST) who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI’s.	Rapid Review Complete	6th October 2014
-	Regorafenib	Stivarga®	For the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.	Assessment Process Complete	1st July 2014
23017	Relugolix	Orgovyx®	Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.	Rapid Review Complete	14th March 2024
21055	Relugolix with estradiol and norethisterone acetate	Ryeqo®	Is indicated for moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Rapid Review Complete	3rd February 2022
24018	Relugolix with estradiol and norethisterone acetate	Ryeqo®	Relugolix with estradiol and norethisterone acetate (Ryeqo®) is Indicated in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.	Rapid Review Complete	15th July 2024
-	Reslizumab	Cinqaero®	Is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.	Rapid Review Complete	1st March 2017
-	Retigabine	Trobalt®	Cost-effectiveness of Retigabine (Trobalt®)	Rapid Review Complete	6th April 2011
24007	Rezafungin	Rezzayo®	Rezafungin (Rezzayo®) is indicated for the treatment of invasive candidiasis in adults.	Rapid Review Complete	26th March 2024
-	Ribociclib	Kisqali®	In combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.	Assessment Process Complete	13th August 2018
-	Ribociclib	Kisqali®	Is indicated in combination with an aromatase inhibitor or fulvestrant for the treatment of pre-, peri- and post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine therapy, or in women who have received prior endocrine therapy:	Rapid Review Complete	11th July 2019
-	Rifaximin	Targaxan®	Is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age.	Rapid Review Complete	7th August 2013
-	Rilpivirine	Edurant®	In combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.	Rapid Review Complete	6th January 2012
-	Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF)	Odefsey®	For the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.	Rapid Review Complete	13th July 2016
22051	Rimegepant	Vydura®	For the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.	NCPE Assessment Process Complete	18th May 2023
-	Rimonabant	Acomplia®	For the management of multiple cardiovascular risks in overweight or obese patients in Ireland	Assessment Process Complete	16th October 2006
-	Riociguat	Adempas®	For the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH).	Rapid Review Complete	20th May 2014
23061	Risankizumab	Skyrizi®	Risankizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy.	NCPE Assessment Process Complete	5th June 2024
22038	Risankizumab	Skyrizi®	Alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).	Rapid Review Complete	30th June 2022